keyword
MENU ▼
Read by QxMD icon Read
search

Phosphate binders

keyword
https://www.readbyqxmd.com/read/28525528/sevelamer-versus-calcium-based-phosphate-binders-for-chronic-kidney-disease
#1
Gonzalo A Bravo-Soto, Trinidad Madrid
Chronic kidney disease-mineral and bone disorder is prevalent. There is controversy regarding whether calcium-based phosphate binders or sevelamer - a non-calcium phosphate binder – constitute a better therapeutic alternative. Searching in Epistemonikos database, which is maintained by screening multiple information sources, we identified 12 systematic reviews comprising 61 studies of which 41 correspond to randomized trials addressing the question of this article. We combined the evidence using meta-analysis and generated a summary of findings following the GRADE approach...
May 12, 2017: Medwave
https://www.readbyqxmd.com/read/28508978/acute-tumoral-calcinosis-due-to-severe-hyperphosphatemia-in-a-maintenance-hemodialysis-patient
#2
Keizo Nishime, Hiroki Takahashi
We report the case of a maintenance hemodialysis patient with severe hyperphosphatemia (26.6 mg/dL) who developed acute tumoral calcinosis. The patient started receiving maintenance hemodialysis after being diagnosed with type 2 diabetes mellitus. The patient's phosphate levels suddenly increased. He had not taken the prescribed phosphate binders for the past 5 years. He noticed swelling of the palmar aspects of his right thumb, which was diagnosed as tumoral calcinosis. His serum phosphate level reached 26...
November 2016: CEN Case Reports
https://www.readbyqxmd.com/read/28508128/the-cardiothoracic-ratio-and-all-cause-and-cardiovascular-disease-mortality-in-patients-undergoing-maintenance-hemodialysis-results-of-the-mbd-5d-study
#3
Hiroaki Ogata, Junji Kumasawa, Shingo Fukuma, Masahide Mizobuchi, Eriko Kinugasa, Masafumi Fukagawa, Shunichi Fukuhara, Tadao Akizawa
BACKGROUND: The cardiothoracic ratio (CTR) is a non-invasive left ventricular hypertrophy index. However, whether CTR associates with cardiovascular disease (CVD) and mortality in hemodialysis (HD) populations is unclear. METHODS: Using a Mineral and Bone disorder Outcomes Study for Japanese CKD Stage 5D Patients (MBD-5D Study) subcohort, 2266 prevalent HD patients (age 62.8 years, female 38.0%, HD duration 9.4 years) with secondary hyperparathyroidism (SHPT) whose baseline CTR had been recorded were selected...
May 15, 2017: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/28499709/mortality-in-dialysis-patients-with-cinacalcet-use-a-large-observational-registry-study
#4
Claudia Friedl, Gilbert Reibnegger, Reinhard Kramar, Emanuel Zitt, Stefan Pilz, Johannes F E Mann, Alexander R Rosenkranz
BACKGROUND: Secondary hyperparathyroidism (sHPT) is associated with higher mortality in dialysis patients. The calcimimetic cinacalcet reduces intact parathyroid hormone (iPTH) in dialysis patients. The randomized controlled EVOLVE trial failed to unequivocally prove survival advantage of cinacalcet in dialysis patients. However, recent post hoc analyses suggested a benefit in subgroups of dialysis patients. Large observational cohort studies may represent an option to better determine such subgroups...
May 9, 2017: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/28464802/phosphate-binders-affect-vitamin-k-concentration-by-undesired-binding-an-in-vitro-study
#5
A Neradova, S P Schumacher, I Hubeek, P Lux, L J Schurgers, M G Vervloet
BACKGROUND: Vascular calcification is a major contributing factor to mortality in end stage renal disease (ESRD). Despite the efficacy of phosphate binders to improve hyperphosphatemia, data on vascular calcification are less clear. There seems to be a difference in attenuation or delay in progression between different binders. In this in vitro experiment we tested whether phosphate binders could limit bioavailability of vitamin K2 by undesired binding. Vitamin K-deficiency limits activation of the vascular tissue mineralization inhibitor matrix γ-carboxyglutamate (Gla) protein (MGP) thereby exacerbating vascular calcification...
May 2, 2017: BMC Nephrology
https://www.readbyqxmd.com/read/28450206/development-of-a-discriminative-biphasic-in-vitro-dissolution-test-and-correlation-with-in-vivo-pharmacokinetic-studies-for-differently-formulated-racecadotril-granules
#6
Jia Deng, Sven Staufenbiel, Shilei Hao, Bochu Wang, Andriy Dashevskiy, Roland Bodmeier
The purpose of this study was to discriminate the release behavior from three differently formulated racecadotril (BCS II) granules and to establish an in vitro-in vivo correlation. Three granule formulations of the lipophilic drug were prepared with equivalent composition but prepared with different manufacturing processes (dry granulation, wet granulation with or without binder). In vitro release of the three granules was investigated using a biphasic dissolution system (phosphate buffer pH6.8 and octanol) and compared to the conventional single phase USP II dissolution test performed under sink and non-sink conditions...
April 25, 2017: Journal of Controlled Release: Official Journal of the Controlled Release Society
https://www.readbyqxmd.com/read/28443351/current-and-future-chemical-therapies-for-treating-anaemia-in-chronic-kidney-disease
#7
Francesco Locatelli, Lucia Del Vecchio, Maria Carmen Luise
Erythropoiesis-stimulating agents (ESAs) are not perfect, since they have potential side effects. Iron therapy is also receiving growing attention in recent years. Areas covered: We performed a literature search on PubMed using the following key words: anemia, chronic kidney disease, HIF stabilisers, sotatercept, actin traps, iron, iron-containing phosphate binders, iron dialysate. We reviewed new drugs that are under clinical development to obtain better safety and activity and/or easier and cheaper manufacturing processes in comparison to available ESAs...
June 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28438255/a-strategy-based-on-patient-preference-improves-the-adherence-and-outcomes-of-phosphate-binders-in-hemodialysis%C3%A2
#8
M Dolores Arenas Jiménez, Eduardo Parra Moncasi, Fernando Álvarez-Ude Cotera
PURPOSE: Phosphate binders (PB) have to be taken with food, their interference with an individual's lifestyle and social habits influences treatment adherence. Several PBs are available, and patient preferences should not be ignored when prescribing. The purpose was to know the extent of intentional and unintentional nonadherence to PB in hemodialysis (HD) patients, and to evaluate the long-term results (adherence, serum phosphate levels, and cost) of a strategy of prescription of PB that takes into account patient preferences...
April 25, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/28429551/the-role-of-calcium-and-non-calcium-based-phosphate-binders-in-chronic-kidney-disease
#9
Grahame J Elder, Jacqueline Center
Rising levels of serum phosphate occur late in the course of chronic kidney disease (CKD) and have been easy targets for nephrologists to treat using phosphate binding drugs, as well as fertile ground for the pharmaceutical industry, for meta-analysis and for the earnest pontifications of guideline writers. Unfortunately, the evidence does little to support this focus, which might be better applied to earlier, adaptive hormonal changes, and to phosphate balance rather than serum phosphate levels. Nevertheless, phosphate binders are ubiquitously prescribed to patients on dialysis, and often prescribed to patients with earlier stages of CKD; for which there is no evidence of benefit and some evidence that calcium-based binders (CBBs) and possibly non-CBBs may cause more harm than placebo...
March 2017: Nephrology
https://www.readbyqxmd.com/read/28425525/exploiting-hydrogen-bonding-interactions-to-probe-smaller-linear-and-cyclic-diamines-binding-to-g-quadruplexes-a-dft-and-molecular-dynamics-study
#10
Mrinal Kanti Si, Anik Sen, Bishwajit Ganguly
G-quadruplexes are formed by the association of four guanine bases through Hoogsteen hydrogen bonding in guanine-rich sequences of DNA and exist in the telomere as well as in promoter regions of certain oncogenes. The sequences of G-quadruplex-DNA are targets for the design of molecules that can bind and can be developed as anti-cancer drugs. The linear and cyclic protonated diamines have been explored to bind to G-quadruplex-DNA through hydrogen bonding interactions. The quadruplex-DNA binders exploit π-stacking and hydrogen bonding interactions with the phosphate backbone of loops and grooves...
April 20, 2017: Physical Chemistry Chemical Physics: PCCP
https://www.readbyqxmd.com/read/28418099/influence-of-divalent-counterions-on-the-dynamics-in-dna-probed-by-a-minor-groove-binder
#11
Sneha Paul, Tasnim Ahmed, Anunay Samanta
Dynamics in DNA to which water, counterions and DNA motions contribute is a topic of considerable interest as it is closely related to the efficiency of biological functions performed by it. Simulation studies and experiments suggest that counterion dynamics in DNA probed by a minor groove binder is similar for various monovalent counterions. As the influence of higher valent counterions, which are also present around DNA and known to bind more strongly to it compared to the monovalent ions, on the dynamics in DNA has not been studied so far, we investigate in this work the dynamics in presence of Mg2+ and Ca2+, chosen for their relative abundance in the cell, using 4', 6-diamidino-2-phenylindole (DAPI), a minor groove-binder, as fluorescence probe...
April 18, 2017: Chemphyschem: a European Journal of Chemical Physics and Physical Chemistry
https://www.readbyqxmd.com/read/28406922/3d-fabrication-and-characterization-of-phosphoric-acid-scaffold-with-a-ha-%C3%AE-tcp-weight-ratio-of-60-40-for-bone-tissue-engineering-applications
#12
Yanen Wang, Kai Wang, Xinpei Li, Qinghua Wei, Weihong Chai, Shuzhi Wang, Yu Che, Tingli Lu, Bo Zhang
A key requirement for three-dimensional printing (3-DP) at room temperature of medical implants depends on the availability of printable and biocompatible binder-powder systems. Different concentration polyvinyl alcohol (PVA) and phosphoric acid solutions were chosen as the binders to make the artificial stent biocompatible with sufficient compressive strength. In order to achieve an optimum balance between the bioceramic powder and binder solution, the biocompatibility and mechanical properties of these artificial stent samples were tested using two kinds of binder solutions...
2017: PloS One
https://www.readbyqxmd.com/read/28398983/effectiveness-of-educational-or-behavioral-interventions-on-adherence-to-phosphate-control-in-adults-receiving-hemodialysis-a-systematic-review
#13
Molly Milazi, Ann Bonner, Clint Douglas
BACKGROUND: People with end-stage kidney disease (ESKD) develop impaired excretion of phosphate. Hyperphosphatemia develops in ESKD as a result of the kidney's reduced ability to excrete ingested phosphate load and is characterized by high bone turnover and increased musculoskeletal morbidity including bone pain and muscle weakness. Increased serum phosphate levels are also associated with cardiovascular disease and associated mortality. These effects are significant considering that cardiovascular disease is the leading cause of death in ESKD, making phosphate control a crucial treatment goal...
April 2017: JBI Database of Systematic Reviews and Implementation Reports
https://www.readbyqxmd.com/read/28391312/calcium-based-phosphate-binders-down-but-not-out
#14
Grahame J Elder
No abstract text is available yet for this article.
January 1, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28349134/sodium-ion-batteries-present-and-future
#15
REVIEW
Jang-Yeon Hwang, Seung-Taek Myung, Yang-Kook Sun
Energy production and storage technologies have attracted a great deal of attention for day-to-day applications. In recent decades, advances in lithium-ion battery (LIB) technology have improved living conditions around the globe. LIBs are used in most mobile electronic devices as well as in zero-emission electronic vehicles. However, there are increasing concerns regarding load leveling of renewable energy sources and the smart grid as well as the sustainability of lithium sources due to their limited availability and consequent expected price increase...
March 28, 2017: Chemical Society Reviews
https://www.readbyqxmd.com/read/28347911/a-simultaneous-stabilization-and-solidification-of-the-top-five-most-toxic-heavy-metals-hg-pb-as-cr-and-cd
#16
Hyun-Taek Kim, Tai Gyu Lee
A novel chemically bonded phosphate ceramic (CBPC) binder was developed for the simultaneous treatment of the top five most toxic heavy metals (Hg, Pb, As, Cr, and Cd). Various CBPC binders were synthesized and tested, and their toxicity characteristic leaching procedure (TCLP) values were obtained. A magnesium/calcium-potassium phosphate ceramic binder with FeCl2 (M/C-KP-FeCl2) simultaneously stabilized multiple heavy metals. The TCLP value of the final product for industrial waste (IW) treatment using the M/C-KP-FeCl2 technology was well below the Universal Treatment Standard (UTS)...
July 2017: Chemosphere
https://www.readbyqxmd.com/read/28339993/one-year-efficacy-and-safety-of-the-iron-based-phosphate-binder-sucroferric-oxyhydroxide-in-patients-on-peritoneal-dialysis
#17
Jürgen Floege, Adrian C Covic, Markus Ketteler, Johannes Mann, Anjay Rastogi, Bruce Spinowitz, Viatcheslav Rakov, Laura J Lisk, Stuart M Sprague
Background.: Sucroferric oxyhydroxide is a noncalcium, iron-based phosphate binder that demonstrated sustained serum phosphorus control, good tolerability and lower pill burden compared with sevelamer carbonate (sevelamer) in a Phase 3 study conducted in dialysis patients. This subanalysis examines the efficacy and tolerability of sucroferric oxyhydroxide and sevelamer in the peritoneal dialysis (PD) patient population. Methods.: The initial study (NCT01324128) and its extension (NCT01464190) were multicenter, Phase 3, open-label, randomized (2:1), active-controlled trials comparing sucroferric oxyhydroxide (1...
February 23, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28336834/-parenteral-calcimimetics-for-the-treatment-of-secondary-hyperparathyroidism
#18
Naoto Hamano, Masafumi Fukagawa
The oral calcimimetics, cinacalcet, is reported to be effective on secondary hyperparathyroidism resistant to classical treatment like phosphate binders or vitamin D receptor activator. The problem that gastrointestinal adverse events cause poor adherence, drug discontinuation, and insufficient dose escalation remains unsolved. The novel injectable calcimimetic, etelcalcetide, is recently developed and is expected to reduce such adverse events and improve the therapeutic effects on moderate to severe secondary hyperparathyroidism...
2017: Clinical Calcium
https://www.readbyqxmd.com/read/28336833/-oral-calcimimetics-on-secondary-hyperparathyroidism-of-uremia
#19
Yasuo Imanishi
Secondary hyperparathyroidism of uremia is associated with poor health outcomes, including all-cause mortality, cardiovascular mortality, and fractures. Standard therapy for secondary hyperparathyroidism includes vitamin D receptor activators, and phosphate binders. Persistently elevated parathyroid hormone(PTH)levels may require the addition of calcimimetics which sensitizes calcium-sensing receptors on the parathyroid glands.
2017: Clinical Calcium
https://www.readbyqxmd.com/read/28306566/anemia-management-in-chronic-kidney-disease-and-dialysis-a-narrative-review
#20
David Collister, Claudio Rigatto, Navdeep Tangri
PURPOSE OF REVIEW: This review describes the current state of anemia management with erythropoietin (EPO)-stimulating agents and iron supplementation in both chronic kidney disease and dialysis patients, with a focus on novel therapies. RECENT FINDINGS: We review the benefits and risks of EPO-stimulating agents, focusing on health-related quality of life and the uncertainties regarding optimal iron utilization in patients with kidney disease. We discuss novel therapies for iron supplementation including iron-based phosphate binders and dialysate iron delivery as well as alternatives to EPO-stimulating agents including hypoxia-inducible factor prolyl hydroxylase inhibitors...
May 2017: Current Opinion in Nephrology and Hypertension
keyword
keyword
119306
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"